Tempest Therapeutics Inc (TPST) FinancialsTPSTFinancialTempest Therapeutics Inc

Evaluating the bottom line, Tempest Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -931.14%, provide a clear picture of how effectively TPST converts its operational activities into shareholder value.

In the context of the broader market, TPST competes directly with industry leaders such as LEXX and RKTO. With a market capitalization of $16.22M, it holds a significant position in the sector. When comparing efficiency, TPST's gross margin of N/A stands against LEXX's 100.00% and RKTO's N/A. Such benchmarking helps identify whether Tempest Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company has reported continuous net losses, with Q2 2026 showing a loss of $5.2 million, an improvement from previous quarters but still concerning. The current ratio has dropped to 0.38, indicating potential liquidity issues.